Aprea Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Aprea Therapeutics, Inc. (APRE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $20.95 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2026-03-16
- Aprea Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2025 was $20.95K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2025-12-31 | $20.95K 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |